Trusted by the partners building the next generation of complex generics.
Airis serves as the R&D execution partner for leading BioPharma developers — running complex generic programs end-to-end, from molecule selection through regulator-cleared dossier. The relationships are long-running, the work is repeat business, and the dossiers stand up to USFDA, MHRA, and Health Canada review.
Aurobindo 
Hetero Labs 
Biocon 
MSN Labs 
Acme Generics 
Amneal 
Belcher Pharma R&D programs executed for the partners who trust us with their most complex molecules.
Across the last several years, Airis has served as the formulation and analytical R&D backbone for some of the most respected names in generic pharmaceuticals. We don't position ourselves as a vendor — we operate as the embedded R&D function for partners who choose to outsource the hardest part of their pipeline to a team that owns the science end-to-end.
These are co-development relationships, not transactional ones. Our partners come back program after program because the work is delivered cleanly: methods that hold up at validation, BE strategies that hold up in front of FDA, and dossiers that don't bounce.
Three reasons our BioPharma partners keep coming back.
Co-development is a long game. The partners who choose Airis stay because the work compounds — methods, analytical platforms, and franchise learnings travel with the relationship across every subsequent program.
End-to-end ownership
From molecule selection and IP positioning through API sourcing, formulation, analytical method science, and dossier filing — one team, one accountable thread. Partners don't manage hand-offs.
Regulator fluency
Deep operational experience filing into USFDA, MHRA, Health Canada, and emerging markets — with a track record of regulator-quiet approvals on the first review cycle. Our partners' dossiers hold up under scrutiny.
Repeat-business economics
Methods, platforms, and learnings travel with the partner across their portfolio. The first program is execution; every program after is leveraged from accumulated franchise knowledge.
Originating our own complex generics for licensure — alongside the co-development work.
In parallel with our partner programs, Airis is actively originating a pipeline of high-barrier complex generics for licensure to dossier developers and B2B platforms. Co-development partners get the embedded R&D function. License partners get a finished, regulator-ready dossier with a pre-qualified manufacturing path attached.